Gsk (GSK) Other Non-Current Liabilities (2009 - 2026)

Gsk (GSK) has 18 years of Other Non-Current Liabilities data on file, last reported at -$1.5 billion in Q2 2026.

• For the quarter ending Q2 2026, Other Non-Current Liabilities fell 9.52% year-over-year to -$1.5 billion; the trailing twelve-month figure through Jun 2026 stood at -$1.5 billion (down 9.52% YoY), and the FY2025 full-year result was -$1.4 billion, up 3.22% from the prior year.
• Other Non-Current Liabilities was -$1.5 billion for Q2 2026 at Gsk, down from -$1.4 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of -$1.0 billion in Q3 2022 to a low of -$8.1 billion in Q1 2022.
• A 5-year average of -$1.7 billion and a median of -$1.4 billion in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 644.72% in 2022 and soared 86.53% in 2023, its largest moves.
• Gsk's Other Non-Current Liabilities stood at -$1.1 billion in 2022, then sank by 30.3% to -$1.4 billion in 2023, then declined by 2.76% to -$1.4 billion in 2024, then increased by 3.62% to -$1.4 billion in 2025, then retreated by 7.37% to -$1.5 billion in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were -$1.5 billion in Q2 2026, -$1.4 billion in Q1 2026, and -$1.4 billion in Q4 2025.